Reduced adenosine triphosphatase activity and motor nerve conduction velocity in l-fucose-fed rats is reversible after dietary normalization☆
References (38)
- et al.
Aldose reductase inhibitors and diabetic complications
Pharmacol Ther
(1992) - et al.
Effect of a new aldose reductase inhibitor, 8′ chloro-2′, 3′ dihydrospiro [pyrrolidine-3, 6′ (5′H)-pyrrolol [1, 2, 3-de][1,4] benzoxazine]-2, 5, 5′-trione in streptozotocin-diabetic rats
Metabolism
(1988) - et al.
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats
Eur J Pharmacol
(1991) - et al.
Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′, 5′-dioxospiro [chroman-4, 4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats
Metabolism
(1992) - et al.
A spectrophotometric method for simultaneous determination of protein-bound hexoses and fucose with a mixture of l-cysteine and phenol
Anal Biochem
(1990) - et al.
Colorimetric assay for free and bound l-fucose
Anal Biochem
(1989) - et al.
Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
N Engl J Med
(1987) Does a common mechanism induce the diverse complications of diabetes?
Diabetes
(1987)- et al.
Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism
Diabetologia
(1994) - et al.
The linked roles of nitric oxide, aldose reductase, and ( in the slowing of nerve conduction in the streptozotocin diabetic rat
J Clin Invest
(1994)
Abnormal sciatic nerve myo-inositol metabolism in the streptozotocin-diabetic rat
Diabetes
Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats
Biochem J
Nerve Na+-K+-ATPase, conduction and myo-inositol in the insulin deficient BB-rat
Am J Physiol
myo-Inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: The effect of aldose reductase inhibition
Diabetologia
Action of sorbinil in diabetic peripheral nerve
Diabetes
Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil
Diabetes
Decreased myo-inositol content and Na+-K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition
Diabetes
Perspectives in diabetes: Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?
Diabetes
Normalization of Na+-K+-ATPase activity in isolated membrane fraction from sciatic nerves of streptozotocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro
Diabetes
Cited by (9)
Safety evaluation of the human-identical milk monosaccharide, l-fucose
2015, Regulatory Toxicology and PharmacologyCitation Excerpt :This hypothesis was borne out by the finding that supplementation of the diet with 1% myo-inositol prevented these changes. The results of the studies by Yorek et al. (1993, 1996) and Sima et al. (1997), however, are of no relevance to the safety assessment of HiMM l-fucose due to the use of dietary concentrations well in excess of those recommended as the maximum to be used in subchronic toxicity studies (i.e., 5% in the diet) so as to avoid effects associated with nutritional and/or caloric imbalances (WHO, 1987). At lower levels of l-fucose exposure, as shown in the current study at 1.0% in the diet, there is no effect of l-fucose administration on indices of neural function, including the results of the FOB testing, clinical/cage-side examinations, and histopathological examination of nerve tissue.
Effect of increased concentration of D-glucose or L-fucose on monocyte adhesion to endothelial cell monolayers and activation of nuclear factor-kB
2002, Metabolism: Clinical and ExperimentalTreatment for Diabetic Peripheral Neuropathy: What have we Learned from Animal Models?
2022, Current Diabetes Reviews
- ☆
Supported by National Institutes of Health Grants No. DK25295 and DK45453 and a grant from the Juvenile Diabetes Foundation (393776).